Roger S McIntyre1, Marie-Josée Filteau2, Lawrence Martin3, Simon Patry4, Andre Carvalho5, Danielle S Cha6, Maxime Barakat7, Maia Miguelez7. 1. Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca. 2. Department of Psychiatry, Laval University, Québec City, QC, Canada; Laval University Robert-Giffard Research Centre, Québec City, QC, Canada; Clinique Marie-Fitzbach, Québec City, QC, Canada. 3. Department of Psychiatry, McMaster University, Hamilton, ON, Canada. 4. Department of Psychiatry, Laval University, Québec City, QC, Canada; Department of Psychiatry, University of Montreal, Montreal, QC, Canada. 5. Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8; Psychiatry Research Group, Federal University of Ceará, Faculty of Medicine, Fortaleza, Ceará, Brazil. 6. Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8. 7. Bristol-Myers Squibb Canada, Montreal, QC, Canada.
Abstract
BACKGROUND: Most adults with major depressive disorder (MDD) fail to achieve remission with index pharmacological treatment. Moreover, at least half will not achieve and sustain remission following multiple pharmacological approaches. Herein, we succinctly review treatment modalities proven effective in treatment-resistant depression (TRD). METHODS: We conducted a review of computerized databases (PubMed, Google Scholar) from 1980 to April 2013. Articles selected for review were based on author consensus, adequacy of sample size, the use of a standardized experimental procedure, validated assessment measures and overall manuscript quality. RESULTS: The evidence base supporting augmentation of conventional antidepressants with atypical antipsychotics (i.e., aripiprazole, quetiapine, and olanzapine) is the most extensive and rigorous of all pharmacological approaches in TRD. Emerging evidence supports the use of some psychostimulants (i.e., lisdexamfetamine) as well as aerobic exercise. In addition, treatments informed by pathogenetic disease models provide preliminary evidence for the efficacy of immune-inflammatory based therapies and metabolic interventions. Manual based psychotherapies remain a treatment option, with the most compelling evidence for cognitive behavioral therapy. Disparate neurostimulation strategies are also available for individuals insufficiently responsive to pharmacotherapy and/or psychosocial interventions. LIMITATIONS: Compared to non-treatment-resistant depression, TRD has been less studied. Most clinical studies on TRD have focused on pharmacotherapy-resistant depression, with relatively fewer studies evaluating "next choice" treatments in individuals who do not initially respond to psychosocial and/or neurostimulatory treatments. CONCLUSION: The pathoetiological heterogeneity of MDD/TRD invites the need for mechanistically dissimilar, and empirically validated, treatment approaches for TRD.
BACKGROUND: Most adults with major depressive disorder (MDD) fail to achieve remission with index pharmacological treatment. Moreover, at least half will not achieve and sustain remission following multiple pharmacological approaches. Herein, we succinctly review treatment modalities proven effective in treatment-resistant depression (TRD). METHODS: We conducted a review of computerized databases (PubMed, Google Scholar) from 1980 to April 2013. Articles selected for review were based on author consensus, adequacy of sample size, the use of a standardized experimental procedure, validated assessment measures and overall manuscript quality. RESULTS: The evidence base supporting augmentation of conventional antidepressants with atypical antipsychotics (i.e., aripiprazole, quetiapine, and olanzapine) is the most extensive and rigorous of all pharmacological approaches in TRD. Emerging evidence supports the use of some psychostimulants (i.e., lisdexamfetamine) as well as aerobic exercise. In addition, treatments informed by pathogenetic disease models provide preliminary evidence for the efficacy of immune-inflammatory based therapies and metabolic interventions. Manual based psychotherapies remain a treatment option, with the most compelling evidence for cognitive behavioral therapy. Disparate neurostimulation strategies are also available for individuals insufficiently responsive to pharmacotherapy and/or psychosocial interventions. LIMITATIONS: Compared to non-treatment-resistant depression, TRD has been less studied. Most clinical studies on TRD have focused on pharmacotherapy-resistant depression, with relatively fewer studies evaluating "next choice" treatments in individuals who do not initially respond to psychosocial and/or neurostimulatory treatments. CONCLUSION: The pathoetiological heterogeneity of MDD/TRD invites the need for mechanistically dissimilar, and empirically validated, treatment approaches for TRD.
Authors: Irena Balzekas; Charles P Lewis; Julia Shekunov; John D Port; Gregory A Worrell; Hang Joon Jo; Paul E Croarkin Journal: Psychiatry Res Neuroimaging Date: 2018-05-31 Impact factor: 2.376
Authors: Roger S McIntyre; Holly X Xiao; Kahlood Syeda; Maj Vinberg; Andre F Carvalho; Rodrigo B Mansur; Nadia Maruschak; Danielle S Cha Journal: CNS Drugs Date: 2015-07 Impact factor: 5.749
Authors: Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey Journal: J Affect Disord Date: 2018-09-19 Impact factor: 4.839
Authors: Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca Journal: Expert Rev Neurother Date: 2017-01-29 Impact factor: 4.618
Authors: Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Robert M Carney; Kenneth E Freedland; Brian C Steinmeyer; Eugene H Rubin; Michael W Rich Journal: J Psychosom Res Date: 2016-07-19 Impact factor: 3.006
Authors: Robert M Carney; Kenneth E Freedland; Brian C Steinmeyer; Eugene H Rubin; Phyllis K Stein; Michael W Rich Journal: J Affect Disord Date: 2016-04-25 Impact factor: 4.839